These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10659047)

  • 41. Immunogenicity and safety of the vaccinia virus LC16m8Δ vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol.
    Sato H; Jing C; Isshiki M; Matsuo K; Kidokoro M; Takamura S; Zhang X; Ohashi T; Shida H
    Vaccine; 2013 Aug; 31(35):3549-57. PubMed ID: 23731631
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The challenges of HIV vaccine development and testing.
    Burgers WA; Williamson C
    Best Pract Res Clin Obstet Gynaecol; 2005 Apr; 19(2):277-91. PubMed ID: 15778116
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guérin expressing human immunodeficiency virus type 1 Gag.
    Kanekiyo M; Matsuo K; Hamatake M; Hamano T; Ohsu T; Matsumoto S; Yamada T; Yamazaki S; Hasegawa A; Yamamoto N; Honda M
    J Virol; 2005 Jul; 79(14):8716-23. PubMed ID: 15994765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys.
    Yasutomi Y; Koenig S; Haun SS; Stover CK; Jackson RK; Conard P; Conley AJ; Emini EA; Fuerst TR; Letvin NL
    J Immunol; 1993 Apr; 150(7):3101-7. PubMed ID: 8454878
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Development of a vaccine against HIV: is this aim accomplishable?].
    Wagner R; Asbach B
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():36-9. PubMed ID: 23961653
    [No Abstract]   [Full Text] [Related]  

  • 46. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant Mycobacterium bovis BCG.
    Bastos RG; Borsuk S; Seixas FK; Dellagostin OA
    Vaccine; 2009 Nov; 27(47):6495-503. PubMed ID: 19720367
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preventive HIV-1 vaccines: where are we going?
    Kent SJ
    Int J STD AIDS; 1998 Dec; 9(12):715-9. PubMed ID: 9874116
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Prospects for vaccine development against HIV infection].
    Kurth R; Binninger D; Ennen J; Denner J; Hartung S; Norley S
    Verh Dtsch Ges Inn Med; 1991; 97():394-402. PubMed ID: 1808921
    [No Abstract]   [Full Text] [Related]  

  • 50. More vaccine efficacy studies on the recombinant Bacille Calmette-Guerin co-expressing Ag85B, Mpt64 and Mtb8.4.
    Qie YQ; Wang JL; Liu W; Shen H; Chen JZ; Zhu BD; Xu Y; Zhang XL; Wang HH
    Scand J Immunol; 2009 Apr; 69(4):342-50. PubMed ID: 19284499
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human versus HIV: round 2 defeat in AIDS vaccine development.
    Lu S
    Expert Rev Vaccines; 2008 Mar; 7(2):151-3. PubMed ID: 18324884
    [No Abstract]   [Full Text] [Related]  

  • 52. Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6.
    Deng YH; He HY; Zhang BS
    J Microbiol Immunol Infect; 2014 Feb; 47(1):48-56. PubMed ID: 23357605
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhancement of cell-mediated immune response in mice by whole HIV-1 gag in Mycobacterium bovis BCG as a live vaccine candidate.
    Promkhatkaew D; Pinyosukhee N; Thongdeejaroen W; Sutthent R; Sawanpanyalert P; Warachit P
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):113-22. PubMed ID: 19323043
    [TBL] [Abstract][Full Text] [Related]  

  • 54. International clinical trials of HIV vaccines: II. phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China.
    Li D; Forrest BD; Li Z; Xue P; Hanson CV; Duan S; Cheng H; Li M; Wang CY; Koff WC
    Asian Pac J Allergy Immunol; 1997 Jun; 15(2):105-13. PubMed ID: 9346275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A review of vaccine research and development: the human immunodeficiency virus (HIV).
    Girard MP; Osmanov SK; Kieny MP
    Vaccine; 2006 May; 24(19):4062-81. PubMed ID: 16530298
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HIV/AIDS vaccines: a need for new concepts?
    Girard MP; Bansal GP
    Int Rev Immunol; 2008; 27(6):447-71. PubMed ID: 19065351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Live recombinant vectors for AIDS vaccine development.
    Voltan R; Robert-Guroff M
    Curr Mol Med; 2003 May; 3(3):273-84. PubMed ID: 12699363
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1: Report from a meeting of the WHO-UNAIDS Vaccine Advisory Committee Geneva, 21-23 February 2000.
    AIDS; 2001 Apr; 15(6):W1-W25. PubMed ID: 11371709
    [No Abstract]   [Full Text] [Related]  

  • 60. "In vitro systems to characterize the immune response to HIV-1 and HIV-1 vaccine candidates", NIAID Workshop Report, Bethesda, August 4, 2010.
    Malaspina A; Rinaldo CR; Sekaly RP; Flores J; D'Souza PM
    Vaccine; 2011 Jun; 29(29-30):4647-53. PubMed ID: 21571022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.